tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Ascites D001201 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Meiser BM and Reichart B New trends in clinical immunosuppression. 1994 Transplant. Proc. pmid:7527954
Nakajima K et al. Effects of triple therapy of cyclosporine, FK 506, and RS-61443 on allogeneic small bowel transplantation in dogs. 1993 Transplant. Proc. pmid:7679821
Ohtsuka S et al. Hamster-to-rat xenotransplantation of whole pancreas by FK 506 combined with splenectomy. 1994 Transplant. Proc. pmid:7513473
Risaliti A et al. Cardiovascular and metabolic complications after liver transplantation: Neoral- versus tacrolimus-based immunosuppression. 2001 Nov-Dec Transplant. Proc. pmid:11750569
Tanabe K et al. Prospective analysis and successful treatment of thrombotic microangiopathy in renal allografts under tacrolimus immunosuppression. 2001 Nov-Dec Transplant. Proc. pmid:11750571
Goto T et al. FK 506: historical perspectives. 1991 Transplant. Proc. pmid:1721254
Ochiai T et al. Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. 1991 Transplant. Proc. pmid:1721255
Ciancio G et al. Current advantage of FK 506 in cadaveric kidney transplantation. 1996 Transplant. Proc. pmid:8623207
Vanrenterghem Y et al. Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. 1998 Transplant. Proc. pmid:9636523
Tanabe K et al. Japanese single-center experience of kidney transplantation under tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11119897
Claesson K et al. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. 1998 Transplant. Proc. pmid:9636524
Lye WC Primary tacrolimus-based immunosuppression in renal allograft recipients: a single center experience. 2000 Transplant. Proc. pmid:11119898
Bruce DS et al. Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9532150
Peddi VR et al. Tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. 1998 Transplant. Proc. pmid:9532151
Ben-Ari Z et al. Comparison of tacrolimus with cyclosporin as primary immunosuppression in patients with hepatitis C virus infection after liver transplantation. 2003 Transplant. Proc. pmid:12644067
Gutiérrez Sánchez MJ et al. Optimization of immunosuppression by switching from azathioprine to enteric-coated mycophenolate sodium in stable kidney transplant patients. 2009 Jul-Aug Transplant. Proc. pmid:19715907
Staschak S et al. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. 1990 Transplant. Proc. pmid:1689896
Lladó L et al. Prospective evaluation of a quadruple therapy based on tacrolimus after liver transplantation. 2002 Transplant. Proc. pmid:11959210
Aptaramanov B et al. A comparison of mycophenolate mofetil with mycophenolate sodium in renal transplant recipients on tacrolimus-based treatment. 2011 Transplant. Proc. pmid:21486609
Ma A et al. Immunological evaluation of combination therapy with tacrolimus and sirolimus on long-term allograft survival in nonhuman primates. 2005 Jan-Feb Transplant. Proc. pmid:15808578
Osako M et al. Alloimmune response may be involved in neointimal hyperplasia in cryopreserved aortic allografts. 2001 Transplant. Proc. pmid:11406250
Mañez R et al. Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation. 1993 Transplant. Proc. pmid:7680170
Müller MK et al. Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. 1991 Transplant. Proc. pmid:1721286
Ketel BL et al. Tacrolimus-based vs cyclosporine-based immunotherapy in combined kidney-pancreas transplantation. 1996 Transplant. Proc. pmid:8623453
Mueller AR et al. Does initial graft function influence the outcome after liver transplantation? 1998 Transplant. Proc. pmid:9636594
Oishi M et al. A case of hyperkalemic distal renal tubular acidosis secondary to tacrolimus in living donor liver transplantation. 2000 Transplant. Proc. pmid:11120143
Soriano S et al. Single-center experience with initial intravenous dosing of tacrolimus after kidney transplantation. 1999 Transplant. Proc. pmid:10576045
Serrano M et al. Clinical value of a single determination of intracellular ATP levels in stimulated CD4+ T lymphocytes in pediatric patients with stable liver transplantation. 2012 Transplant. Proc. pmid:23146475
Takeuchi H et al. Lymphocyte sensitivity to cyclosporine and tacrolimus in chronic renal failure patients and clinical significance in renal transplantation. 1998 Transplant. Proc. pmid:9474950
Díaz-Molina B et al. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. 2012 Transplant. Proc. pmid:23146479
Liu M et al. C4d-positive acute humoral renal allograft rejection: rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil. 2004 Transplant. Proc. pmid:15518760
Deardon DJ et al. Small bowel tonometry: a possible technique for detecting early small bowel allograft dysfunction. 1993 Transplant. Proc. pmid:7505502
Hayashi S et al. Synergistic effect of donor pretreatment using FK 506 in hamster-to-rat cardiac xenotransplantation. 1994 Transplant. Proc. pmid:7518126
Ohtsuka S et al. Mechanism of antibody production in guinea pig to rat discordant xenotransplant: establishment of a simple model by intravenous injection of discordant splenocytes. 1994 Transplant. Proc. pmid:7518130
Marente VC et al. Modigraf administration through jejunostomy in liver transplant recipient: case report. 2013 Transplant. Proc. pmid:24314992
Woodle ES et al. FK 506 rescue therapy: early conversion improves efficacy. 1993 Transplant. Proc. pmid:7682359
Loss M et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. 1995 Transplant. Proc. pmid:7533365
Yagihashi A et al. The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721318
Ziolkowski J et al. Effect of immunosuppressive regimen on acute rejection and liver graft function. 2003 Transplant. Proc. pmid:14529915
Kato T et al. FK506 may suppress liver injury during the early period following living-related liver transplantation. 2003 Transplant. Proc. pmid:12591316
Bahra M et al. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. 2005 Transplant. Proc. pmid:15919436
Maes BD and Vanrenterghem YF Cyclosporine: advantages versus disadvantages vis-à-vis tacrolimus. 2004 Transplant. Proc. pmid:15041305
Ã…berg F et al. Asymptomatic De Novo Inflammatory Bowel Disease Late After Liver Transplantation for Primary Sclerosing Cholangitis: A Case Report. 2015 Transplant. Proc. pmid:26680092
Malireddy SR et al. Altered first-pass effects in a liver transplant recipient explained intraindividual variation in calcineurin inhibitor concentrations: a case report. 2008 Transplant. Proc. pmid:18589198
Braun F et al. Therapeutic drug monitoring of tacrolimus early after liver transplantation. 2002 Transplant. Proc. pmid:12176473
Tashiro H et al. Monitoring for engraftment of rat orthotopic liver transplantation by semiquantitative PCR. 1995 Transplant. Proc. pmid:7533421
Schorlemmer HU et al. Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. 1998 Transplant. Proc. pmid:9865312
Felser I et al. Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721350
Chiereghin A et al. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients. 2010 Jan-Feb Transplant. Proc. pmid:20172283
Dierickx D et al. Thrombotic microangiopathy following intestinal transplantation: a single center experience. 2010 Jan-Feb Transplant. Proc. pmid:20172285
Nanni G et al. Lack of correlation between serum levels of mycophenolate mofetil and kidney transplant outcome in tacrolimus-based immunosupression. 2002 Transplant. Proc. pmid:12270323
Pape L et al. Long-term stable glomerular filtration rate achieved with tacrolimus in pediatric renal transplantation. 2002 Transplant. Proc. pmid:12270367
Prasad GV et al. Role of dietary salt intake in posttransplant hypertension with tacrolimus-based immunosuppression. 2005 Transplant. Proc. pmid:15919496
Walgenbach KJ et al. Increased presence of mast cells and interleukin-4 during chronic rejection of rat intestinal allografts. 1996 Transplant. Proc. pmid:8907896
Miyagi M et al. Comparison of the therapeutic effects between CsA and FK506 on chronic renal allograft injury and TGF-beta expression. 2002 Transplant. Proc. pmid:12176497
Nüssler NC et al. CD8+ host cells infiltrate the intestinal mucosa after allogeneic small bowel transplantation even in the absence of acute rejection. 1996 Transplant. Proc. pmid:8907898
van Hooff JP et al. Benelux experience with a combination of tacrolimus and mycophenolate mofetil: 4-year results. 2002 Transplant. Proc. pmid:12176498
Malaise J et al. Immunosuppressive drugs after simultaneous pancreas-kidney transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182827
Zmonarski SC et al. Lowering of Messenger Ribonucleic Acid Toll-Like Receptors 2-4,9 in Peripheral Blood Mononuclear Cells in Kidney Allograft Recipients, Relationships With Immunosuppressive Treatment, and Delayed Graft Function Occurrence. 2016 Transplant. Proc. pmid:27496439
Oishi M et al. Successful swine small bowel transplantation using FK506: effect on endotoxin translocation. 1994 Transplant. Proc. pmid:7520629
Moutabarrik A et al. FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. 1991 Transplant. Proc. pmid:1721382
Takeda M et al. Immunologic factors contributing to acute rejection in lungs xenotransplanted between primates. 1998 Transplant. Proc. pmid:9838670
Murase N et al. Immunomodulation of intestinal transplant with allograft irradiation and simultaneous donor bone marrow infusion. 1999 Feb-Mar Transplant. Proc. pmid:10083238
Endoh M et al. Nonmuscle myosin heavy chain and metalloproteinase-2 expression in concordant pulmonary xenografts. 2000 Transplant. Proc. pmid:10936397
Gassel HJ et al. Selective immunosuppression induces tolerance after liver transplantation: an immunohistochemical and cytofluorographic analysis of the graft and recipient immune system. 1997 Feb-Mar Transplant. Proc. pmid:9123253
Kliem V et al. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. 1996 Transplant. Proc. pmid:8962227
Citterio F et al. Steroid withdrawal from tacrolimus-based therapy in renal transplant patients. 2002 Transplant. Proc. pmid:12176545
Han DJ et al. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen. 2012 Transplant. Proc. pmid:22310592
Chang HR et al. Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients. 2007 Transplant. Proc. pmid:17580178
Jiang H et al. IL-10: a tacrolimus-specific cytotoxic mediator in ongoing allograft rejection. 2001 Feb-Mar Transplant. Proc. pmid:11266931
Orsenigo R et al. FK506 and SMS 201-995: effect on heterotopic heart transplantation in rats. 2001 Feb-Mar Transplant. Proc. pmid:11266956
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation in rats. 1991 Transplant. Proc. pmid:1721413
Tanabe K et al. Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression. 1996 Transplant. Proc. pmid:8658670
Nakao A et al. Cytokine mRNA expression on rat small bowel allograft treated with tacrolimus and simultaneous bone marrow transplantation via the portal vein. 2000 Transplant. Proc. pmid:10995965
Yamashita T et al. Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. 1991 Transplant. Proc. pmid:1721414
Sugito K et al. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression. 1996 Transplant. Proc. pmid:8658683
Soltero L et al. Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects. 2003 Transplant. Proc. pmid:12826147
Langer RM et al. De novo tumors after kidney transplantation: the Budapest experience. 2003 Transplant. Proc. pmid:12826170
Glanemann M et al. Higher immunosuppressive efficacy of mycophenolate mofetil in combination with FK 506 than in combination with cyclosporine A. 2000 Transplant. Proc. pmid:10812095
McMaster P et al. Liver transplantation: changing goals in immunosuppression. 1998 Transplant. Proc. pmid:9723295
Fábrega E et al. Effect of immunosuppressant blood levels on serum concentration of interleukin-17 and -23 in stable liver transplant recipients. 2009 Transplant. Proc. pmid:19376417
Tahir W et al. Diffuse Alveolar haemorrhage: a fatal complication after alemtuzumab induction therapy in renal transplantation. Transplant. Proc. pmid:25645795
Burke GW et al. Steroid-resistant acute rejection following SPK: importance of maintaining therapeutic dosing in a triple-drug regimen. 2002 Transplant. Proc. pmid:12176628
Kovarik JM et al. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. 2006 Transplant. Proc. pmid:17175302
Moura Neto A et al. Clinical Profile of Patients With Diabetes Mellitus and Liver Transplantation: Results After a Multidisciplinary Team Intervention. 2018 Transplant. Proc. pmid:29661438
Mühlbacher F Tacrolimus versus cyclosporin microemulsion in liver transplantation: results of a 3-month study. 2001 Feb-Mar Transplant. Proc. pmid:11267317
Duzova A et al. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. 2003 Transplant. Proc. pmid:14697926
Lin CY et al. Effects of FK 506 on the biochemical markers in canine lung allograft rejection. 1991 Transplant. Proc. pmid:1721445
Morales E et al. Conversion from cyclosporine to FK 506 as rescue therapy in renal transplantation with poorly steroid-responsive acute rejection. 1999 Transplant. Proc. pmid:10500562
Jost U et al. FK 506 treatment of intractable rejection after liver transplantation. 1993 Transplant. Proc. pmid:7689276
Nardo B et al. Evidence of microchimerism after pretransplant blood transfusion and FK 506 in liver xenograft. 2000 Transplant. Proc. pmid:11134771
Miyata Y et al. Development of xenogeneic microchimerism correlated with graft outcome in hamster-to-rat heart xenotransplantation. 1998 Transplant. Proc. pmid:9723548
Chamienia A et al. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results. 2014 Transplant. Proc. pmid:25380901
Kocak H et al. Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: better 2-year graft and patient survival than with a higher mycophenolate mofetil dose. 2005 Transplant. Proc. pmid:16213288
Abou-Jaoude MM et al. Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients. 2005 Transplant. Proc. pmid:16213293
Abe T et al. Risk factors for development of new-onset diabetes mellitus and progressive impairment of glucose metabolism after living-donor liver transplantation. 2014 Transplant. Proc. pmid:24767367
Reimer J et al. Quality of life after kidney transplantation--the impact of tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267573
McLaughlin GE et al. Effect of aminophylline on urine flow in children with tacrolimus-induced renal insufficiency. 2000 Transplant. Proc. pmid:10856596
Fritsche L et al. Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients. 1998 Transplant. Proc. pmid:9636481
Bresci S et al. Case report: cystic fibrosis, lung transplantation, and the novel H1N1 flu. 2010 Jul-Aug Transplant. Proc. pmid:20692461